Insider Selling: Lyell Immunopharma (NASDAQ:LYEL) Insider Sells $24,989.28 in Stock

Lyell Immunopharma, Inc. (NASDAQ:LYEL) insider David Shook sold 1,977 shares of the company’s stock in a transaction on Wednesday, June 10th. The shares were sold at an average price of $12.64, for a total transaction of $24,989.28. Following the transaction, the insider owned 20,923 shares of the company’s stock, valued at approximately $264,466.72. The trade was a 8.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Lyell Immunopharma Price Performance

NASDAQ:LYEL opened at $13.50 on Friday. Lyell Immunopharma, Inc. has a one year low of $8.46 and a one year high of $45.00. The stock has a market cap of $314.96 million, a P/E ratio of -0.98 and a beta of -0.09. The company has a fifty day moving average price of $19.17 and a 200 day moving average price of $23.26.

Lyell Immunopharma (NASDAQ:LYEL) last announced its quarterly earnings data on Wednesday, May 6th. The company reported ($1.10) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($1.10). Lyell Immunopharma had a negative net margin of 794,858.12% and a negative return on equity of 85.71%. The company had revenue of $0.00 million during the quarter, compared to analysts’ expectations of $0.00 million. As a group, equities research analysts anticipate that Lyell Immunopharma, Inc. will post -7.87 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the stock. Robert W. Baird set a $49.00 price objective on shares of Lyell Immunopharma and gave the stock an “outperform” rating in a report on Thursday, April 30th. Needham & Company LLC reiterated a “buy” rating and issued a $44.00 price objective on shares of Lyell Immunopharma in a report on Monday, June 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Lyell Immunopharma in a research note on Tuesday, April 21st. Citigroup restated a “market outperform” rating on shares of Lyell Immunopharma in a research note on Tuesday. Finally, Citizens Jmp began coverage on shares of Lyell Immunopharma in a research note on Monday, March 9th. They set a “market outperform” rating and a $34.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $43.00.

Institutional Investors Weigh In On Lyell Immunopharma

A number of large investors have recently bought and sold shares of the company. Charles Schwab Investment Management Inc. grew its stake in Lyell Immunopharma by 7.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 85,423 shares of the company’s stock worth $2,629,000 after buying an additional 5,913 shares in the last quarter. BBR Partners LLC acquired a new position in shares of Lyell Immunopharma in the fourth quarter valued at approximately $210,000. ExodusPoint Capital Management LP acquired a new position in shares of Lyell Immunopharma in the fourth quarter valued at approximately $262,000. Marshall Wace LLP bought a new stake in shares of Lyell Immunopharma in the 2nd quarter valued at $94,000. Finally, Two Sigma Investments LP grew its holdings in Lyell Immunopharma by 107.0% during the 3rd quarter. Two Sigma Investments LP now owns 20,827 shares of the company’s stock worth $338,000 after acquiring an additional 10,768 shares during the period. 66.05% of the stock is currently owned by institutional investors and hedge funds.

About Lyell Immunopharma

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.